Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
about
Metabolic signals in sleep regulation: recent insightsClinical management of sleep disturbances in Alzheimer's disease: current and emerging strategiesProfile of suvorexant in the management of insomniaNeural plasticity in hypocretin neurons: the basis of hypocretinergic regulation of physiological and behavioral functions in animalsSuvorexant in insomnia: efficacy, safety and place in therapyOX1 and OX2 orexin/hypocretin receptor pharmacogeneticsCrystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexantStructure and ligand-binding mechanism of the human OX1 and OX2 orexin receptorsInhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in MonkeysDifferential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulatorsOrexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs.Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in miceClinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies.Integrating modern concepts of insomnia and its contemporary treatment into primary care.Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptorStrategies of Functional Foods Promote Sleep in Human Being.The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice.A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.Differential actions of orexin receptors in brainstem cholinergic and monoaminergic neurons revealed by receptor knockouts: implications for orexinergic signaling in arousal and narcolepsy.Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators.Orexin/hypocretin receptor signalling: a functional perspective.Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism.Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?Orexin/hypocretin receptor signalling cascades.Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Orexin receptor antagonists--a patent review (2010 to August 2014).Small-molecule antagonists of the orexin receptors.Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure.Orexin/hypocretin neuron activation is correlated with alcohol seeking and preference in a topographically specific manner.Interaction Between Orexin-A and Sleep Quality in Females in Extreme Weight Conditions.On and Off switches in the brain.Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics.The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine.Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study.Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach.In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans.Orexin-1 receptor signalling in the prelimbic cortex and ventral tegmental area regulates cue-induced reinstatement of ethanol-seeking in iP rats.Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain.
P2860
Q26770483-B44D731E-95D9-4559-8889-0C9755994F63Q26772851-C5006868-ADCB-4758-BF7D-945FD6F37BE3Q26773214-6B33E558-42C7-4F0D-9A60-0E91B0883B56Q26779699-4D17159B-40F3-4B3D-B7DF-5ECCA1F9FD8FQ26781955-8EEFF583-179D-4ABD-BE6E-84B318FB7F52Q26865384-006A3C02-713A-4631-9ABF-1FC267C6D258Q27696899-4A0FC8D2-946A-4F4E-ADAA-9FC939ACF18FQ27704228-62FDA2A4-60B6-4277-9DC2-3D6D6746A9EDQ30375507-E10EA81B-4D35-431B-AE58-12A0FB46C2B7Q30423240-BA5807BE-401B-41F9-AF9D-B16D284F31FEQ30437151-4F243AAB-91C2-4AEC-B911-65A8ECAF0FB3Q30570222-B45E1B0A-6CB0-4EBC-BD58-89934FD796C1Q31171354-C73A4E04-BC3E-4A0C-8F7B-0C8CE7B5D546Q33568609-F8DC5E23-B9FA-4309-B6BA-73ABF554A3DFQ34442421-477A48E0-84C0-407D-AB56-7E4B7E77D480Q35450376-124FEDBC-C531-42DB-8D1B-B10614849CA0Q35633066-EA7C269C-9A78-46D6-BB5E-FD159A473A84Q36731312-325082EE-DC1B-4464-9426-2A7FF47610E1Q37220464-FCBA0DF6-88C2-4443-9E34-F63C7433FF44Q37406178-17978D19-E5EB-4473-8DF9-5E4DE9E803D3Q37411777-731805B7-99EC-4E95-BC6E-BEE162E0283DQ37522864-FF6047AF-3D46-44F3-B998-518BA099BB55Q37583131-DE73E97D-9D1D-41AC-B580-8A3FE72D8D1BQ37670707-0158CB03-59A4-40BD-B8C7-50AEDB3B0585Q38125537-1831C41A-9112-4BAB-B231-71C03F288564Q38250849-CA340656-AE4B-4465-94E0-3AB1417F164CQ38269308-7960C0A2-CE06-47DE-950D-C7DC28EACE07Q38285705-8712F3D2-FF5F-427D-9539-197C8C832698Q38743165-39FC1110-67C2-44F8-959F-16E4266423EFQ38845354-0E00FBE7-4D20-4086-B100-7BCC1B4158B2Q38849902-B26B9A04-2CC5-4C0C-B975-9947707571A8Q39244986-8B2E021E-1C2A-43F5-9D90-BF6CD9618C4CQ40058614-B05CFA9D-4FF7-41E3-BCB1-806D342D7338Q44349574-36202C69-E356-4DC3-B057-83738E6BA7A9Q47738084-9134E2A3-735A-4BFF-B92F-FF3C37798EBEQ47747316-34C8CFDD-3577-4AF9-9842-67D8D272C070Q47839193-EFD4C72B-BD90-4E13-8439-24521B0BFDE4Q47888898-8E9F041E-5CB7-4008-A822-471D723DFC4CQ48217405-F08F2ABF-A5BB-45C8-9CF1-B9BCE78D9027Q48689667-F8CC334D-2659-4AA2-B98E-60B96AC09E21
P2860
Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
@en
Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
@nl
type
label
Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
@en
Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
@nl
prefLabel
Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
@en
Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
@nl
P2860
P356
P1476
Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
@en
P2093
J J Renger
P2860
P304
P356
10.1111/BPH.12261
P407
P577
2014-01-01T00:00:00Z